{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:35:57Z","timestamp":1792521357501,"version":"4.5.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Microbiol Biotechnol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    is a nosocomial Gram-negative pathogen of multi- and extensive-drug resistance phenotypes. In certain regions, multi-drug resistance rates can soar as high as 80\u201390%. Accordingly, reports by the World Health Organization and the Centers for Disease Control and Prevention underscore the urgent need for developing new antibiotics against\n                    <jats:italic>A. baumannii<\/jats:italic>\n                    . With the scarcity of novel antibiotics against this pathogen in the development pipeline, its rapid ability to develop and acquire resistance, and its versatile virulence weaponry, antivirulence therapeutics that can attenuate its virulence without adversely affecting growth may represent a promising treatment option with less selective pressure for resistance development. This review summarizes different antivirulence strategies against\n                    <jats:italic>A. baumannii<\/jats:italic>\n                    , which have been preclinically tested in various in vivo models. We also review different challenges and opportunities related to the realization of\n                    <jats:italic>A. baumannii<\/jats:italic>\n                    antivirulence drugs for clinical use.\n                  <\/jats:p>","DOI":"10.1007\/s11274-025-04593-3","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T04:32:39Z","timestamp":1761798759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antivirulence drugs against Acinetobacter baumannii: where do they stand?"],"prefix":"10.1007","volume":"41","author":[{"given":"Aya A.","family":"Elanany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany G.","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"58","key":"4593_CR1","doi-asserted-by":"publisher","first-page":"36459","DOI":"10.1039\/d1ra06238g","volume":"11","author":"RH Abd El-Aleam","year":"2021","unstructured":"Abd El-Aleam RH, George RF, Georgey HH, Abdel-Rahman HM (2021) Bacterial virulence factors: a target for heterocyclic compounds to combat bacterial resistance. RSC Adv 11(58):36459\u201336482. https:\/\/doi.org\/10.1039\/d1ra06238g","journal-title":"RSC Adv"},{"key":"4593_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ijbiomac.2022.12.045","volume":"226","author":"G Abirami","year":"2023","unstructured":"Abirami G, Alexpandi R, Sudhin S, Durgadevi R, Roshni PS, Kumar P, Veera Ravi A (2023) Pyrogallol downregulates the expression of virulence-associated proteins in Acinetobacter baumannii and showing anti-infection activity by improving non-specific immune response in zebrafish model. Int J Biol Macromol 226:853\u2013869. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.12.045","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"4593_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00203-020-02026-3","volume":"203","author":"G Abirami","year":"2021","unstructured":"Abirami G, Durgadevi R, Velmurugan P, Ravi AV (2021) Gene expressing analysis indicates the role of Pyrogallol as a novel antibiofilm and antivirulence agent against Acinetobacter baumannii. Arch Microbiol 203(1):251\u2013260. https:\/\/doi.org\/10.1007\/s00203-020-02026-3","journal-title":"Arch Microbiol"},{"issue":"1","key":"4593_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4161\/viru.1.1.10210","volume":"1","author":"LA Actis","year":"2010","unstructured":"Actis LA (2010) Insight into innovative approaches to battle Acinetobacter baumannii infection therapy struggles. Virulence 1(1):6\u20137. https:\/\/doi.org\/10.4161\/viru.1.1.10210","journal-title":"Virulence"},{"issue":"4","key":"4593_CR5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/nrmicro3232","volume":"12","author":"RC Allen","year":"2014","unstructured":"Allen RC, Popat R, Diggle SP, Brown SP (2014) Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol 12(4):300\u2013308. https:\/\/doi.org\/10.1038\/nrmicro3232","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"4593_CR6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2174\/1389450121666201023122355","volume":"22","author":"NI Bamunuarachchi","year":"2021","unstructured":"Bamunuarachchi NI, Khan F, Kim YM (2021) Inhibition of virulence factors and biofilm formation of Acinetobacter baumannii by naturally-derived and synthetic drugs. Curr Drug Targets 22(7):734\u2013759. https:\/\/doi.org\/10.2174\/1389450121666201023122355","journal-title":"Curr Drug Targets"},{"issue":"1","key":"4593_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.mib.2009.12.003","volume":"13","author":"C Baron","year":"2010","unstructured":"Baron C (2010) Antivirulence drugs to target bacterial secretion systems. Curr Opin Microbiol 13(1):100\u2013105. https:\/\/doi.org\/10.1016\/j.mib.2009.12.003","journal-title":"Curr Opin Microbiol"},{"key":"4593_CR8","doi-asserted-by":"publisher","unstructured":"Bisaro F, Jackson-Litteken CD, McGuffey JC, Hooppaw AJ, Bodrog S, Jebeli L, Ortiz-Marquez JC, van Opijnen T, Scott NE, Di Venanzio G, Feldman MF (2024) Diclofenac sensitizes multi-drug resistant Acinetobacter baumannii to colistin. bioRxi. https:\/\/doi.org\/10.1101\/2024.05.17.594771","DOI":"10.1101\/2024.05.17.594771"},{"issue":"8","key":"4593_CR9","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/infdis\/jiu593","volume":"211","author":"KW Bruhn","year":"2015","unstructured":"Bruhn KW, Pantapalangkoor P, Nielsen T, Tan B, Junus J, Hujer KM, Wright MS, Bonomo RA, Adams MD, Chen W, Spellberg B (2015) Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremia. J Infect Dis 211(8):1296--1305. https:\/\/doi.org\/10.1093\/infdis\/jiu593","journal-title":"J Infect Dis"},{"key":"4593_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2022.105855","volume":"173","author":"S de Buchhorn Freitas","year":"2022","unstructured":"de Buchhorn Freitas S, Hartwig DD (2022) Promising targets for immunotherapeutic approaches against Acinetobacter baumannii. Microb Pathog 173:105855. https:\/\/doi.org\/10.1016\/j.micpath.2022.105855","journal-title":"Microb Pathog"},{"key":"4593_CR11","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.3762\/bjoc.14.239","volume":"14","author":"MB Calvert","year":"2018","unstructured":"Calvert MB, Jumde VR, Titz A (2018) Pathoblockers or antivirulence drugs as a new option for the treatment of bacterial infections. Beilstein J Org Chem 14:2607\u20132617. https:\/\/doi.org\/10.3762\/bjoc.14.239","journal-title":"Beilstein J Org Chem"},{"key":"4593_CR12","doi-asserted-by":"publisher","unstructured":"Casadevall A, Paneth N (2024) Monoclonal antibody therapies for infectious diseases. In: Current topics in microbiology and immunology . Springer Berlin Heidelberg, pp 1\u201311. https:\/\/doi.org\/10.1007\/82_2024_265","DOI":"10.1007\/82_2024_26"},{"key":"4593_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.micpath.2014.10.007","volume":"77","author":"S Cascioferro","year":"2014","unstructured":"Cascioferro S, Totsika M, Schillaci D (2014) Sortase A: an ideal target for anti-virulence drug development. Microb Pathog 77:105\u2013112. https:\/\/doi.org\/10.1016\/j.micpath.2014.10.007","journal-title":"Microb Pathog"},{"issue":"1","key":"4593_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrmicro1818","volume":"6","author":"L Cegelski","year":"2008","unstructured":"Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ (2008) The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 6(1):17\u201327. https:\/\/doi.org\/10.1038\/nrmicro1818","journal-title":"Nat Rev Microbiol"},{"key":"4593_CR15","unstructured":"Centers for Disease Control and Prevention (2019) 2019 AR Threats Report. https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html"},{"issue":"8","key":"4593_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2471\/blt.22.288313","volume":"100","author":"C Chamas","year":"2022","unstructured":"Chamas C, Barbeitas MM, Correa M, Kameda K, de Oliveira ACD, Villarinho L (2022) Innovation in diagnostics: addressing gaps in low- and middle-income countries. Bull World Health Organ 100(8):467\u2013467a. https:\/\/doi.org\/10.2471\/blt.22.288313","journal-title":"Bull World Health Organ"},{"key":"4593_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.845500","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Liu M, Zhang P, Xu M, Yuan W, Bian L, Liu Y, Xia J, Leung SSY (2022) Phage-derived depolymerase as an antibiotic adjuvant against multidrug-resistant Acinetobacter baumannii. Front Microbiol 13:845500. https:\/\/doi.org\/10.3389\/fmicb.2022.845500","journal-title":"Front Microbiol"},{"issue":"1","key":"4593_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4014\/jmb.1804.03051","volume":"29","author":"U Choi","year":"2019","unstructured":"Choi U, Lee CR (2019) Antimicrobial agents that inhibit the outer membrane assembly machines of Gram-negative bacteria. J Microbiol Biotechnol 29(1):1\u201310. https:\/\/doi.org\/10.4014\/jmb.1804.03051","journal-title":"J Microbiol Biotechnol"},{"issue":"9","key":"4593_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nchembio.2007.24","volume":"3","author":"AE Clatworthy","year":"2007","unstructured":"Clatworthy AE, Pierson E, Hung DT (2007) Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3(9):541\u2013548. https:\/\/doi.org\/10.1038\/nchembio.2007.24","journal-title":"Nat Chem Biol"},{"issue":"2","key":"4593_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1473-3099(15)00466-1","volume":"16","author":"L Czaplewski","year":"2016","unstructured":"Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock REW, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, \u00d3lafsd\u00f3ttir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH (2016) Alternatives to antibiotics\u2014a pipeline portfolio review. Lancet Infect Dis 16(2):239\u2013251. https:\/\/doi.org\/10.1016\/S1473-3099(15)00466-1","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"4593_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1586\/14787210.2015.1025055","volume":"13","author":"C Dexter","year":"2015","unstructured":"Dexter C, Murray GL, Paulsen IT, Peleg AY (2015) Community-acquired Acinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis. Expert Rev Anti-infect Ther 13(5):567\u2013573. https:\/\/doi.org\/10.1586\/14787210.2015.1025055","journal-title":"Expert Rev Anti-infect Ther"},{"issue":"1","key":"4593_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/mi.2017.50","volume":"11","author":"N Dikshit","year":"2018","unstructured":"Dikshit N, Kale SD, Khameneh HJ, Balamuralidhar V, Tang CY, Kumar P, Lim TP, Tan TT, Kwa AL, Mortellaro A, Sukumaran B (2018) Nlrp3 inflammasome pathway has a critical role in the host immunity against clinically relevant Acinetobacter baumannii pulmonary infection. Mucosal Immunol 11(1):257\u2013272. https:\/\/doi.org\/10.1038\/mi.2017.50","journal-title":"Mucosal Immunol"},{"issue":"9","key":"4593_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biology11091343","volume":"11","author":"KG Dolma","year":"2022","unstructured":"Dolma KG, Khati R, Paul AK, Rahmatullah M, de Lourdes Pereira M, Wilairatana P, Khandelwal B, Gupta C, Gautam D, Gupta M, Goyal RK, Wiart C, Nissapatorn V (2022) Virulence characteristics and emerging therapies for biofilm-forming Acinetobacter baumannii: a review. Biology 11(9):1343. https:\/\/doi.org\/10.3390\/biology11091343","journal-title":"Biology"},{"issue":"11","key":"4593_CR24","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/jac\/dks275","volume":"67","author":"TP Dorlo","year":"2012","unstructured":"Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ (2012) Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 67(11):2576\u20132597. https:\/\/doi.org\/10.1093\/jac\/dks275","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4593_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12010077","volume":"12","author":"WH Elwakil","year":"2023","unstructured":"Elwakil WH, Rizk SS, El-Halawany AM, Rateb ME, Attia AS (2023) Multidrug-resistant Acinetobacter baumannii infections in the United Kingdom versus Egypt: trends and potential natural products solutions. Antibiotics 12(1):77. https:\/\/doi.org\/10.3390\/antibiotics12010077","journal-title":"Antibiotics"},{"issue":"4","key":"4593_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cbpa.2008.06.022","volume":"12","author":"S Escaich","year":"2008","unstructured":"Escaich S (2008) Antivirulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol 12(4):400\u2013408. https:\/\/doi.org\/10.1016\/j.cbpa.2008.06.022","journal-title":"Curr Opin Chem Biol"},{"key":"4593_CR27","unstructured":"European Centre for Disease Prevention and Control, & WHO Regional Office for Europe (2024) Surveillance of antimicrobial resistance in Europe, 2023 data: executive summary. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2023-data-executive-summary"},{"key":"4593_CR28","doi-asserted-by":"publisher","unstructured":"European Centre for Disease Prevention and Control, & World Health Organization (2023) Antimicrobial resistance surveillance in Europe 2023\u20132021 data. Publications Office of the European Union. https:\/\/doi.org\/10.2900\/63495","DOI":"10.2900\/63495"},{"key":"4593_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01409-18","author":"SE Fiester","year":"2019","unstructured":"Fiester SE, Arivett BA, Beckett AC, Wagner BR, Ohneck EJ, Schmidt RE, Grier JT, Actis LA (2019) Miltefosine reduces the cytolytic activity and virulence of Acinetobacter baumannii. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01409-18","journal-title":"Antimicrob Agents Chemother"},{"key":"4593_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00074","volume":"9","author":"O Fleitas Martinez","year":"2019","unstructured":"Fleitas Martinez O, Cardoso MH, Ribeiro SM, Franco OL (2019) Recent advances in anti-virulence therapeutic strategies with a focus on dismantling bacterial membrane microdomains, toxin neutralization, quorum-sensing interference and biofilm inhibition. Front Cell Infect Microbiol 9:74. https:\/\/doi.org\/10.3389\/fcimb.2019.00074","journal-title":"Front Cell Infect Microbiol"},{"key":"4593_CR31","doi-asserted-by":"publisher","unstructured":"Galac MR, Snesrud E, Lebreton F, Stam J, Julius M, Ong AC, Maybank R, Jones AR, Kwak YI, Hinkle K, Waterman PE, Lesho EP, Bennett JW, Gann PM (2020) A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development. Antimicrob Agents Chemother 64(10). https:\/\/doi.org\/10.1128\/aac.00840-20","DOI":"10.1128\/aac.00840-20"},{"issue":"22","key":"4593_CR32","doi-asserted-by":"publisher","first-page":"6840","DOI":"10.1128\/aem.02378-13","volume":"79","author":"R Garc\u00eda-Contreras","year":"2013","unstructured":"Garc\u00eda-Contreras R, Maeda T, Wood TK (2013) Resistance to quorum-quenching compounds. Appl Environ Microbiol 79(22):6840\u20136846. https:\/\/doi.org\/10.1128\/aem.02378-13","journal-title":"Appl Environ Microbiol"},{"key":"4593_CR33","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Pati\u00f1o MG, Garc\u00eda-Contreras R, Licona-Lim\u00f3n P (2017) The immune response against Acinetobacter baumannii, an emerging pathogen in nosocomial infections [mini review]. Front Immunol 8. https:\/\/doi.org\/10.3389\/fimmu.2017.00441","DOI":"10.3389\/fimmu.2017.00441"},{"key":"4593_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00310-16","author":"A Giammanco","year":"2017","unstructured":"Giammanco A, Cal\u00e0 C, Fasciana T, Dowzicky MJ (2017) Global assessment of the activity of Tigecycline against multidrug-resistant gram-negative pathogens between 2004 and 2014 as part of the Tigecycline evaluation and surveillance trial. mSphere. https:\/\/doi.org\/10.1128\/mSphere.00310-16","journal-title":"mSphere"},{"key":"4593_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14050967","author":"K Golberg","year":"2022","unstructured":"Golberg K, Markus V, Kagan BE, Barzanizan S, Yaniv K, Teral\u0131 K, Kramarsky-Winter E, Marks RS, Kushmaro A (2022) Anti-virulence activity of 3,3\u2019-Diindolylmethane (DIM): a bioactive cruciferous phytochemical with accelerated wound healing benefits. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14050967","journal-title":"Pharmaceutics"},{"key":"4593_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.744494","volume":"12","author":"T Guo","year":"2021","unstructured":"Guo T, Li M, Sun X, Wang Y, Yang L, Jiao H, Li G (2021) Synergistic activity of capsaicin and colistin against colistin-resistant Acinetobacter baumannii: in vitro\/vivo efficacy and mode of action. Front Pharmacol 12:744494. https:\/\/doi.org\/10.3389\/fphar.2021.744494","journal-title":"Front Pharmacol"},{"issue":"2","key":"4593_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nrmicro.2017.148","volume":"16","author":"CM Harding","year":"2018","unstructured":"Harding CM, Hennon SW, Feldman MF (2018) Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol 16(2):91\u2013102. https:\/\/doi.org\/10.1038\/nrmicro.2017.148","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"4593_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90208-4","volume":"11","author":"HF Hetta","year":"2021","unstructured":"Hetta HF, Al-Kadmy IMS, Khazaal SS, Abbas S, Suhail A, El-Mokhtar MA, Ellah NHA, Ahmed EA, Abd-ellatief RB, El-Masry EA, Batiha GE-S, Elkady AA, Mohamed NA, Algammal AM (2021) Antibiofilm and antivirulence potential of silver nanoparticles against multidrug-resistant Acinetobacter baumannii. Sci Rep 11(1):10751. https:\/\/doi.org\/10.1038\/s41598-021-90208-4","journal-title":"Sci Rep"},{"key":"4593_CR39","unstructured":"Hoffmann-La R (2024) A study to investigate the pharmacokinetics of RO7223280 in critically ill participants with bacterial infections. https:\/\/clinicaltrials.gov\/study\/NCT05614895"},{"issue":"3","key":"4593_CR40","doi-asserted-by":"publisher","first-page":"e01863","DOI":"10.1128\/mbio.01863-21","volume":"13","author":"J Hooppaw Anna","year":"2022","unstructured":"Hooppaw Anna J, McGuffey Jenna C, Di Venanzio G, Ortiz-Marquez Juan C, Weber Brent S, Lightly Tasia J, van Opijnen T, Scott Nichollas E, Cardona Silvia T, Feldman Mario F (2022) The phenylacetic acid catabolic pathway regulates antibiotic and oxidative stress responses in Acinetobacter. mBio 13(3):e01863-01821. https:\/\/doi.org\/10.1128\/mbio.01863-21","journal-title":"mBio"},{"issue":"10","key":"4593_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9102049","volume":"9","author":"JA Hotinger","year":"2021","unstructured":"Hotinger JA, Morris ST, May AE (2021) The case against antibiotics and for anti-virulence therapeutics. Microorganisms 9(10):2049. https:\/\/doi.org\/10.3390\/microorganisms9102049","journal-title":"Microorganisms"},{"issue":"5748","key":"4593_CR42","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1126\/science.1116739","volume":"310","author":"DT Hung","year":"2005","unstructured":"Hung DT, Shakhnovich EA, Pierson E, Mekalanos JJ (2005) Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310(5748):670\u2013674. https:\/\/doi.org\/10.1126\/science.1116739","journal-title":"Science"},{"key":"4593_CR43","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.mib.2019.10.008","volume":"51","author":"MI Hutchings","year":"2019","unstructured":"Hutchings MI, Truman AW, Wilkinson B (2019) Antibiotics: past, present and future. Curr Opin Microbiol 51:72\u201380. https:\/\/doi.org\/10.1016\/j.mib.2019.10.008","journal-title":"Curr Opin Microbiol"},{"issue":"12","key":"4593_CR44","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/iub.531","volume":"63","author":"F Imperi","year":"2011","unstructured":"Imperi F, Antunes LC, Blom J, Villa L, Iacono M, Visca P, Carattoli A (2011) The genomics of Acinetobacter baumannii: insights into genome plasticity, antimicrobial resistance and pathogenicity\u00a0[Research Support, Non-U.S. Gov\u2019t Review]. IUBMB life 63(12):1068\u20131074. https:\/\/doi.org\/10.1002\/iub.531","journal-title":"IUBMB life"},{"issue":"1","key":"4593_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37749-6","volume":"14","author":"C Jonkergouw","year":"2023","unstructured":"Jonkergouw C, Beyeh NK, Osmekhina E, Leskinen K, Taimoory SM, Fedorov D, Anaya-Plaza E, Kostiainen MA, Trant JF, Ras RHA, Saavalainen P, Linder MB (2023) Repurposing host-guest chemistry to sequester virulence and eradicate biofilms in multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Nat Commun 14(1):2141. https:\/\/doi.org\/10.1038\/s41467-023-37749-6","journal-title":"Nat Commun"},{"key":"4593_CR46","unstructured":"Knight Therapeutics Inc (2010) Miltefosine to treat mucocutaneous leishmaniasis. https:\/\/clinicaltrials.gov\/study\/NCT01050907"},{"issue":"11","key":"4593_CR47","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1099\/mic.0.27954-0","volume":"151","author":"B Koch","year":"2005","unstructured":"Koch B, Liljefors T, Persson T, Nielsen J, Kjelleberg S, Givskov M (2005) The LuxR receptor: the sites of interaction with quorum-sensing signals and inhibitors. Microbiology 151(11):3589\u20133602. https:\/\/doi.org\/10.1099\/mic.0.27954-0","journal-title":"Microbiology"},{"issue":"10","key":"4593_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9102104","volume":"9","author":"S Kumar","year":"2021","unstructured":"Kumar S, Anwer R, Azzi A (2021) Virulence potential and treatment options of multidrug-resistant (MDR) Acinetobacter baumannii. Microorganisms 9(10):2104. https:\/\/doi.org\/10.3390\/microorganisms9102104","journal-title":"Microorganisms"},{"issue":"8","key":"4593_CR49","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1007\/s00253-017-8224-6","volume":"101","author":"A Latka","year":"2017","unstructured":"Latka A, Maciejewska B, Majkowska-Skrobek G, Briers Y, Drulis-Kawa Z (2017) Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process. Appl Microbiol Biotechnol 101(8):3103\u20133119. https:\/\/doi.org\/10.1007\/s00253-017-8224-6","journal-title":"Appl Microbiol Biotechnol"},{"key":"4593_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104429","author":"WYV Lau","year":"2023","unstructured":"Lau WYV, Taylor PK, Brinkman FSL, Lee AHY (2023) Pathogen-associated gene discovery workflows for novel antivirulence therapeutic development. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104429","journal-title":"EBioMedicine"},{"issue":"6","key":"4593_CR51","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0092-8674(03)00422-7","volume":"113","author":"K Lauber","year":"2003","unstructured":"Lauber K, Bohn E, Kr\u00f6ber SM, Xiao Y-j, Blumenthal SG, Lindemann RK, Marini P, Wiedig C, Zobywalski A, Baksh S, Xu Y, Autenrieth IB, Schulze-Osthoff K, Belka C, Stuhler G, Wesselborg S (2003) Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113(6):717\u2013730. https:\/\/doi.org\/10.1016\/S0092-8674(03)00422-7","journal-title":"Cell"},{"key":"4593_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2022.127032","volume":"260","author":"SKK Law","year":"2022","unstructured":"Law SKK, Tan HS (2022) The role of quorum sensing, biofilm formation, and iron acquisition as key virulence mechanisms in Acinetobacter baumannii and the corresponding anti-virulence strategies. Microbiol Res 260:127032. https:\/\/doi.org\/10.1016\/j.micres.2022.127032","journal-title":"Microbiol Res"},{"issue":"12","key":"4593_CR53","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","volume":"13","author":"R Laxminarayan","year":"2013","unstructured":"Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O (2013) Antibiotic resistance\u2014the need for global solutions. Lancet Infect Dis 13(12):1057\u20131098. https:\/\/doi.org\/10.1016\/S1473-3099(13)70318-9","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"4593_CR54","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.coph.2003.04.001","volume":"3","author":"YM Lee","year":"2003","unstructured":"Lee YM, Almqvist F, Hultgren SJ (2003) Targeting virulence for antimicrobial chemotherapy. Curr Opin Pharmacol 3(5):513\u2013519. https:\/\/doi.org\/10.1016\/j.coph.2003.04.001","journal-title":"Curr Opin Pharmacol"},{"key":"4593_CR55","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00312-12","author":"L Lin","year":"2012","unstructured":"Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, Bonomo RA, Fernandez L, Hancock RE, Adams MD, French SW, Buslon VS, Spellberg B (2012) Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. mBio. https:\/\/doi.org\/10.1128\/mBio.00312-12","journal-title":"mBio"},{"key":"4593_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00545","volume":"10","author":"Y Liu","year":"2019","unstructured":"Liu Y, Leung SSY, Guo Y, Zhao L, Jiang N, Mi L, Li P, Wang C, Qin Y, Mi Z, Bai C, Gao Z (2019) The capsule depolymerase Dpo48 rescues Galleria mellonella and mice from Acinetobacter baumannii systemic infections. Front Microbiol 10:545. https:\/\/doi.org\/10.3389\/fmicb.2019.00545","journal-title":"Front Microbiol"},{"issue":"4","key":"4593_CR57","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ijantimicag.2016.01.015","volume":"47","author":"SH Lob","year":"2016","unstructured":"Lob SH, Hoban DJ, Sahm DF, Badal RE (2016) Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents 47(4):317\u2013323. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.01.015","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"4593_CR58","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1586\/eri.13.11","volume":"11","author":"R L\u00f3pez-Rojas","year":"2013","unstructured":"L\u00f3pez-Rojas R, Smani Y, Pach\u00f3n J (2013) Treating multidrug-resistant Acinetobacter baumannii infection by blocking its virulence factors. Expert Rev Anti-infect Ther 11(3):231\u2013233. https:\/\/doi.org\/10.1586\/eri.13.11","journal-title":"Expert Rev Anti-infect Ther"},{"issue":"1","key":"4593_CR59","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2023.2289769","volume":"15","author":"M Lucidi","year":"2024","unstructured":"Lucidi M, Visaggio D, Migliaccio A, Capecchi G, Visca P, Imperi F, Zarrilli R (2024) Pathogenicity and virulence of Acinetobacter baumannii: factors contributing to the fitness in healthcare settings and the infected host. Virulence 15(1):2289769. https:\/\/doi.org\/10.1080\/21505594.2023.2289769","journal-title":"Virulence"},{"key":"4593_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060570","author":"C Ma","year":"2021","unstructured":"Ma C, McClean S (2021) Mapping global prevalence of Acinetobacter baumannii and recent vaccine development to tackle it. Vaccines. https:\/\/doi.org\/10.3390\/vaccines9060570","journal-title":"Vaccines"},{"issue":"3","key":"4593_CR61","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/ismej.2011.122","volume":"6","author":"T Maeda","year":"2012","unstructured":"Maeda T, Garc\u00eda-Contreras R, Pu M, Sheng L, Garcia LR, Tom\u00e1s M, Wood TK (2012) Quorum quenching quandary: resistance to antivirulence compounds. ISME J 6(3):493\u2013501. https:\/\/doi.org\/10.1038\/ismej.2011.122","journal-title":"ISME J"},{"issue":"13","key":"4593_CR62","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","volume":"370","author":"SS Magill","year":"2014","unstructured":"Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK (2014) Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370(13):1198\u20131208. https:\/\/doi.org\/10.1056\/NEJMoa1306801","journal-title":"N Engl J Med"},{"issue":"1","key":"4593_CR63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/jac\/dkz409","volume":"75","author":"M Mart\u00ednez-Guiti\u00e1n","year":"2020","unstructured":"Mart\u00ednez-Guiti\u00e1n M, V\u00e1zquez-Ucha JC, \u00c1lvarez-Fraga L, Conde-P\u00e9rez K, Bou G, Poza M, Beceiro A (2020) Antisense inhibition of lpxB gene expression in Acinetobacter baumannii by peptide-PNA conjugates and synergy with colistin. J Antimicrob Chemother 75(1):51\u201359. https:\/\/doi.org\/10.1093\/jac\/dkz409","journal-title":"J Antimicrob Chemother"},{"key":"4593_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.mib.2016.06.001","volume":"33","author":"D Maura","year":"2016","unstructured":"Maura D, Ballok AE, Rahme LG (2016) Considerations and caveats in anti-virulence drug development. Curr Opin Microbiol 33:41\u201346. https:\/\/doi.org\/10.1016\/j.mib.2016.06.001","journal-title":"Curr Opin Microbiol"},{"key":"4593_CR65","doi-asserted-by":"publisher","unstructured":"McCarthy RR, Larrouy-Maumus GJ, Meiqi Tan MGC, Wareham DW (2021) Antibiotic resistance mechanisms and their transmission in Acinetobacter baumannii. In: Kishore U (ed.) Microbial pathogenesis: infection and immunity. Springer International Publishing, pp 135\u2013153. https:\/\/doi.org\/10.1007\/978-3-030-67452-6_7","DOI":"10.1007\/978-3-030-67452-6_7"},{"issue":"12","key":"4593_CR66","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1128\/iai.00683-08","volume":"76","author":"RD Mesquita","year":"2008","unstructured":"Mesquita RD, Carneiro AB, Bafica A, Gazos-Lopes F, Takiya CM, Souto-Padron T, Vieira DP, Ferreira-Pereira A, Almeida IC, Figueiredo RT, Porto BN, Bozza MT, Gra\u00e7a-Souza AV, Lopes AHCS, Atella GC, Silva-Neto MAC (2008) Trypanosoma cruzi infection is enhanced by vector saliva through immunosuppressant mechanisms mediated by lysophosphatidylcholine. Infect Immun 76(12):5543\u20135552. https:\/\/doi.org\/10.1128\/iai.00683-08","journal-title":"Infect Immun"},{"issue":"2","key":"4593_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10020194","volume":"10","author":"A Mir\u00f3-Canturri","year":"2021","unstructured":"Mir\u00f3-Canturri A, Ayerbe-Algaba R, Jim\u00e9nez-Mej\u00edas ME, Pach\u00f3n J, Smani Y (2021) Efficacy of lysophosphatidylcholine as direct treatment in combination with colistin against Acinetobacter baumannii in murine severe infections models. Antibiotics 10(2):194. https:\/\/doi.org\/10.3390\/antibiotics10020194","journal-title":"Antibiotics"},{"key":"4593_CR68","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00778-17","author":"KH Moon","year":"2017","unstructured":"Moon KH, Weber BS, Feldman MF (2017) Subinhibitory concentrations of trimethoprim and sulfamethoxazole prevent biofilm formation by Acinetobacter baumannii through inhibition of Csu pilus expression. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00778-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4593_CR69","doi-asserted-by":"publisher","unstructured":"Morris FC, Dexter C, Kostoulias X, Uddin MI, Peleg AY (2019) The mechanisms of disease caused by acinetobacter baumannii [review]. Front Microbiol 10. https:\/\/doi.org\/10.3389\/fmicb.2019.01601","DOI":"10.3389\/fmicb.2019.01601"},{"key":"4593_CR70","doi-asserted-by":"publisher","unstructured":"M\u00fchlen S, Dersch P (2016) Anti-virulence strategies to target bacterial infections. In: Stadler M, Dersch P (eds) How to overcome the antibiotic crisis: facts, challenges, technologies and future perspectives. Springer International Publishing, pp 147\u2013183. https:\/\/doi.org\/10.1007\/82_2015_490","DOI":"10.1007\/82_2015_490"},{"issue":"10325","key":"4593_CR71","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC, Browne AJ, Chipeta MG, Fell F, Hackett S, Haines-Woodhouse G, Hamadani BHK, Kumaran EAP, McManigal B, Achalapong S, Agarwal R, Akech S, Albertson S, Amuasi J, Andrews J, Aravkin A, Ashley E, Babin F-X, Bailey F, Baker S, Basnyat B, Bekker A, Bender R, Berkley JA, Bethou A, Bielicki J, Boonkasidecha S, Bukosia J, Carvalheiro C, Casta\u00f1eda-Orjuela C, Chansamouth V, Chaurasia S, Chiurchi\u00f9 S, Chowdhury F, Donatien RC, Cook AJ, Cooper B, Cressey TR, Criollo-Mora E, Cunningham M, Darboe S, Day NPJ, De Luca M, Dokova K, Dramowski A, Dunachie SJ, Bich TD, Eckmanns T, Eibach D, Emami A, Feasey N, Fisher-Pearson N, Forrest K, Garcia C, Garrett D, Gastmeier P, Giref AZ, Greer RC, Gupta V, Haller S, Haselbeck A, Hay SI, Holm M, Hopkins S, Hsia Y, Iregbu KC, Jacobs J, Jarovsky D, Javanmardi F, Jenney AWJ, Khorana M, Kissoon N, Kobeissi E, Kostyanev T, Phommasone K, Khusuwan S, Krapp F, Krumkamp R, Kumar A, Kyu HH, Lim C, Lim K, Limmathurotsakul D, Loftus MJ, Lunn M, Ma J, Manoharan A, Marks F, May J, Mayxay M, Mturi N, Munera-Huertas T, Musicha P, Musila LA, Mussi-Pinhata MM, Naidu RN, Nakamura T, Nanavati R, Nangia S, Newton P, Ngoun C, Novotney A, Nwakanma D, Obiero CW, Ochoa TJ, Olivas-Martinez A, Olliaro P, Ooko E, Ortiz-Brizuela E, Ounchanum P, Pak GD, Paredes JL, Peleg AY, Perrone C, Phe T, Plakkal N, Ponce-de-Leon A, Raad M, Ramdin T, Rattanavong S, Riddell A, Roberts T, Robotham JV, Roca A, Rosenthal VD, Rudd KE, Russell N, Sader HS, Saengchan W, Schnall J, Scott JAG, Seekaew S, Sharland M, Shivamallappa M, Sifuentes-Osornio J, Steenkeste AJSN, Stewardson AJ, Stoeva T, Tasak N, Thaiprakong A, Thwaites G, Tigoi C, Turner C, Turner P, van Doorn HR, Velaphi S, Vongpradith A, Vongsouvath M, Vu H, Walsh T, Walson JL, Waner S, Wangrangsimakul T, Wannapinij P, Wozniak T, Young-Sharma TEMW, Yu KC, Zheng P, Sartorius B, Lopez AD, Stergachis A, Moore C, Dolecek C, Naghavi M (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399(10325):629\u2013655. https:\/\/doi.org\/10.1016\/s0140-6736(21)02724-0","journal-title":"Lancet"},{"issue":"9","key":"4593_CR72","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s12275-021-1394-z","volume":"59","author":"SH Na","year":"2021","unstructured":"Na SH, Jeon H, Oh MH, Kim YJ, Lee JC (2021) Screening of small molecules attenuating biofilm formation of Acinetobacter baumannii by inhibition of ompA promoter activity. J Microbiol 59(9):871\u2013878. https:\/\/doi.org\/10.1007\/s12275-021-1394-z","journal-title":"J Microbiol"},{"issue":"3","key":"4593_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24030378","volume":"24","author":"N Neville","year":"2019","unstructured":"Neville N, Jia Z (2019) Approaches to the structure-based design of antivirulence drugs: therapeutics for the post-antibiotic era. Molecules 24(3):378. https:\/\/doi.org\/10.3390\/molecules24030378","journal-title":"Molecules"},{"issue":"4","key":"4593_CR74","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/infdis\/jix315","volume":"216","author":"TB Nielsen","year":"2017","unstructured":"Nielsen TB, Pantapalangkoor P, Luna BM, Bruhn KW, Yan J, Dekitani K, Hsieh S, Yeshoua B, Pascual B, Vinogradov E, Hujer KM, Domitrovic TN, Bonomo RA, Russo TA, Lesczcyniecka M, Schneider T, Spellberg B (2017) Monoclonal antibody protects against Acinetobacter baumannii infection by enhancing bacterial clearance and evading sepsis. J Infect Dis 216(4):489\u2013501. https:\/\/doi.org\/10.1093\/infdis\/jix315","journal-title":"J Infect Dis"},{"issue":"9","key":"4593_CR75","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/infdis\/jiac499","volume":"227","author":"TB Nielsen","year":"2023","unstructured":"Nielsen TB, Yan J, Slarve M, Li R, Junge JA, Luna BM, Wilkinson I, Yerramalla U, Spellberg B (2023) Development of a bispecific antibody targeting clinical isolates of Acinetobacter baumannii. J Infect Dis 227(9):1042\u20131049. https:\/\/doi.org\/10.1093\/infdis\/jiac499","journal-title":"J Infect Dis"},{"key":"4593_CR76","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00162-21","author":"TB Nielsen","year":"2021","unstructured":"Nielsen TB, Yan J, Slarve M, Lu P, Li R, Ruiz J, Lee B, Burk E, Talyansky Y, Oelschlaeger P, Hurth K, Win W, Luna BM, Bonomo RA, Spellberg B (2021) Monoclonal antibody therapy against Acinetobacter baumannii. Infect Immun. https:\/\/doi.org\/10.1128\/iai.00162-21","journal-title":"Infect Immun"},{"key":"4593_CR77","unstructured":"O\u2019Neill J (2016) Tackling drug-resistant infections globally: final report and recommendations. The review on antimicrobial resistance. https:\/\/amr-review.org\/sites\/default\/files\/160525_Final%20paper_with%20cover.pdf"},{"issue":"1","key":"4593_CR78","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41429-020-0344-z","volume":"74","author":"H Ogawara","year":"2021","unstructured":"Ogawara H (2021) Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs. J Antibiot (Tokyo) 74(1):24\u201341. https:\/\/doi.org\/10.1038\/s41429-020-0344-z","journal-title":"J Antibiot (Tokyo)"},{"key":"4593_CR79","doi-asserted-by":"publisher","DOI":"10.1128\/aem.00934-19","author":"H Oliveira","year":"2019","unstructured":"Oliveira H, Mendes A, Fraga AG, Ferreira A, Pimenta AI, Mil-Homens D, Fialho AM, Pedrosa J, Azeredo J (2019) K2 capsule depolymerase is highly stable, is refractory to resistance, and protects larvae and mice from Acinetobacter baumannii sepsis. Appl Environ Microbiol. https:\/\/doi.org\/10.1128\/aem.00934-19","journal-title":"Appl Environ Microbiol"},{"issue":"8","key":"4593_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30093-8","volume":"18","author":"S Ombelet","year":"2018","unstructured":"Ombelet S, Ronat J-B, Walsh T, Yansouni CP, Cox J, Vlieghe E, Martiny D, Semret M, Vandenberg O, Jacobs J, Lunguya O, Phoba M-F, Lompo P, Phe T, Kariuki S, Newton PN, Dance DAB, Muvunyi C, El Safi S, Barbe B, Falay D, Affolabi D, Page M, Langendorf C, Gille Y, Leenstra T, Stelling J, Naas T, Kesteman T, Seifu D, Delarocque-Astagneau E, Schultsz C, Schutt-Gerowitt H, Letchford J, Wertheim H, Kahlmeter G, Aidara Kane A (2018) Clinical bacteriology in low-resource settings: today\u2019s solutions. Lancet Infect Dis 18(8):e248-e258. https:\/\/doi.org\/10.1016\/S1473-3099(18)30093-8","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"4593_CR81","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1128\/aac.02708-15","volume":"60","author":"R Parra Mill\u00e1n","year":"2016","unstructured":"Parra Mill\u00e1n R, Jim\u00e9nez Mej\u00edas ME, S\u00e1nchez Encinales V, Ayerbe Algaba R, Guti\u00e9rrez Valencia A, Pach\u00f3n Ib\u00e1\u00f1ez ME, D\u00edaz C, P\u00e9rez Del Palacio J, L\u00f3pez Cort\u00e9s LF, Pach\u00f3n J, Smani Y (2016) Efficacy of lysophosphatidylcholine in combination with antimicrobial agents against Acinetobacter baumannii in experimental murine peritoneal sepsis and pneumonia models. Antimicrob Agents Chemother 60(8):4464\u20134470. https:\/\/doi.org\/10.1128\/aac.02708-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"4593_CR82","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1093\/jac\/dky343","volume":"73","author":"R Parra-Mill\u00e1n","year":"2018","unstructured":"Parra-Mill\u00e1n R, Vila-Farr\u00e9s X, Ayerbe-Algaba R, Varese M, S\u00e1nchez-Encinales V, Bay\u00f3 N, Pach\u00f3n-Ib\u00e1\u00f1ez ME, Teixid\u00f3 M, Vila J, Pach\u00f3n J, Giralt E, Smani Y (2018) Synergistic activity of an OmpA inhibitor and colistin against colistin-resistant Acinetobacter baumannii: mechanistic analysis and in vivo efficacy. J Antimicrob Chemother 73(12):3405\u20133412. https:\/\/doi.org\/10.1093\/jac\/dky343","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4593_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-022-02438-9","volume":"22","author":"M Pourhajibagher","year":"2022","unstructured":"Pourhajibagher M, Pourakbari B, Bahador A (2022) Contribution of antimicrobial photo-sonodynamic therapy in wound healing: an in vivo effect of curcumin-nisin-based poly (L-lactic acid) nanoparticle on Acinetobacter baumannii biofilms. BMC Microbiol 22(1):28. https:\/\/doi.org\/10.1186\/s12866-022-02438-9","journal-title":"BMC Microbiol"},{"key":"4593_CR84","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1465-0691.2004.1007.x","volume":"10","author":"JH Powers","year":"2004","unstructured":"Powers JH (2004) Antimicrobial drug development \u2013 the past, the present, and the future. Clin Microbiol Infect 10:23\u201331. https:\/\/doi.org\/10.1111\/j.1465-0691.2004.1007.x","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"4593_CR85","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1179\/2047773215y.0000000030","volume":"109","author":"F Prestinaci","year":"2015","unstructured":"Prestinaci F, Pezzotti P, Pantosti A (2015) Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health 109(7):309\u2013318. https:\/\/doi.org\/10.1179\/2047773215y.0000000030","journal-title":"Pathog Glob Health"},{"issue":"2","key":"4593_CR86","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nrd3013","volume":"9","author":"DA Rasko","year":"2010","unstructured":"Rasko DA, Sperandio V (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9(2):117\u2013128. https:\/\/doi.org\/10.1038\/nrd3013","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"4593_CR87","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1128\/aac.01665-09","volume":"54","author":"T Reddy","year":"2010","unstructured":"Reddy T, Chopra T, Marchaim D, Pogue JM, Alangaden G, Salimnia H, Boikov D, Navon-Venezia S, Akins R, Selman P, Dhar S, Kaye KS (2010) Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob Agents Chemother 54(5):2235\u20132238. https:\/\/doi.org\/10.1128\/aac.01665-09","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4593_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03031-4","volume":"23","author":"OD Reyes-Hern\u00e1ndez","year":"2023","unstructured":"Reyes-Hern\u00e1ndez OD, Figueroa-Gonz\u00e1lez G, Quintas-Granados LI, Guti\u00e9rrez-Ru\u00edz SC, Hern\u00e1ndez-Parra H, Romero-Montero A, Del Prado-Audelo ML, Bernal-Chavez SA, Cort\u00e9s H, Pe\u00f1a-Corona SI, Kiyekbayeva L, Ate\u015f\u015fahin DA, Goloshvili T, Leyva-G\u00f3mez G, Sharifi-Rad J (2023) 3,3\u2032-diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways. Cancer Cell Int 23(1):180. https:\/\/doi.org\/10.1186\/s12935-023-03031-4","journal-title":"Cancer Cell Int"},{"issue":"8","key":"4593_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000805","volume":"18","author":"C Rezzoagli","year":"2020","unstructured":"Rezzoagli C, Archetti M, Mignot I, Baumgartner M, K\u00fcmmerli R (2020) Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa. PLoS Biol 18(8):e3000805. https:\/\/doi.org\/10.1371\/journal.pbio.3000805","journal-title":"PLoS Biol"},{"issue":"1","key":"4593_CR90","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1128\/aac.01314-12","volume":"57","author":"JM Rolain","year":"2013","unstructured":"Rolain JM, Diene SM, Kempf M, Gimenez G, Robert C, Raoult D (2013) Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pan-drug-resistant Acinetobacter baumannii isolate from Marseille, France. Antimicrobal Agents and Chemotherapy 57(1):592\u2013596. https:\/\/doi.org\/10.1128\/aac.01314-12","journal-title":"Antimicrobal Agents and Chemotherapy"},{"issue":"9","key":"4593_CR91","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1128\/iai.00366-10","volume":"78","author":"TA Russo","year":"2010","unstructured":"Russo TA, Luke Nicole R, Beanan Janet M, Olson R, Sauberan Shauna L, MacDonald U, Schultz LW, Umland Timothy C, Campagnari Anthony A (2010) The K1 capsular polysaccharide of Acinetobacter baumannii strain 307\u20130294 Is a major virulence factor. Infect Immun 78(9):3993\u20134000. https:\/\/doi.org\/10.1128\/iai.00366-10","journal-title":"Infect Immun"},{"issue":"3","key":"4593_CR92","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1128\/iai.01184-12","volume":"81","author":"TA Russo","year":"2013","unstructured":"Russo TA, Beanan JM, Olson R, MacDonald U, Cox AD, Michael FS, Vinogradov EV, Spellberg B, Luke-Marshall NR, Campagnari AA (2013) The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun 81(3):915\u2013922. https:\/\/doi.org\/10.1128\/iai.01184-12","journal-title":"Infect Immun"},{"issue":"6","key":"4593_CR93","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/infdis\/jiv533","volume":"213","author":"TA Russo","year":"2016","unstructured":"Russo TA, Spellberg B, Johnson JR (2016) Important complexities of the antivirulence target paradigm: a novel ostensibly resistance-avoiding approach for treating infections. J Infect Dis 213(6):901\u2013903. https:\/\/doi.org\/10.1093\/infdis\/jiv533","journal-title":"J Infect Dis"},{"key":"4593_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2023.127345","volume":"271","author":"YNV Sabino","year":"2023","unstructured":"Sabino YNV, Cotter PD, Mantovani HC (2023) Anti-virulence compounds against Staphylococcus aureus associated with bovine mastitis: a new therapeutic option? Microbiol Res 271:127345. https:\/\/doi.org\/10.1016\/j.micres.2023.127345","journal-title":"Microbiol Res"},{"issue":"7","key":"4593_CR95","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1128\/jb.185.7.2066-2079.2003","volume":"185","author":"M Schuster","year":"2003","unstructured":"Schuster M, Lostroh CP, Ogi T, Greenberg EP (2003) Identification, timing, and signal specificity of Pseudomonas aeruginosa quorum-controlled genes: a transcriptome analysis. J Bacteriol 185(7):2066\u20132079. https:\/\/doi.org\/10.1128\/jb.185.7.2066-2079.2003","journal-title":"J Bacteriol"},{"key":"4593_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1053968","volume":"13","author":"A Shadan","year":"2023","unstructured":"Shadan A, Pathak A, Ma Y, Pathania R, Singh RP (2023) Deciphering the virulence factors, regulation, and immune response to Acinetobacter baumannii infection. Front Cell Infect Microbiol 13:1053968. https:\/\/doi.org\/10.3389\/fcimb.2023.1053968","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"4593_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10030279","volume":"10","author":"M Shahed-Al-Mahmud","year":"2021","unstructured":"Shahed-Al-Mahmud M, Roy R, Sugiokto FG, Islam MN, Lin M-D, Lin L-C, Lin N-T (2021) Phage \u03c6AB6-borne depolymerase combats Acinetobacter baumannii biofilm formation and infection. Antibiotics 10(3):279. https:\/\/doi.org\/10.3390\/antibiotics10030279","journal-title":"Antibiotics"},{"key":"4593_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1332108","volume":"15","author":"J Shi","year":"2024","unstructured":"Shi J, Cheng J, Liu S, Zhu Y, Zhu M (2024) Acinetobacter baumannii: an evolving and cunning opponent. Front Microbiol 15:1332108. https:\/\/doi.org\/10.3389\/fmicb.2024.1332108","journal-title":"Front Microbiol"},{"issue":"3","key":"4593_CR99","doi-asserted-by":"publisher","first-page":"e00086","DOI":"10.1128\/aac.00086-23","volume":"67","author":"M Slarve","year":"2023","unstructured":"Slarve M, Reyna Z, Burk E, Ruiz-Delgado J, Li R, Yan J, Luna B, Spellberg B (2023) Therapeutic, humanized monoclonal antibody exhibits broad binding and protective efficacy against Acinetobacter baumannii. Antimicrob Agents Chemother 67(3):e00086-00023. https:\/\/doi.org\/10.1128\/aac.00086-23","journal-title":"Antimicrob Agents Chemother"},{"key":"4593_CR100","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.174799","author":"MJ Slarve","year":"2024","unstructured":"Slarve MJ, Bowler N, Burk E, Yan J, Carlino-MacDonald U, Russo TA, Luna BM, Spellberg B (2024) Clinical assays rapidly predict bacterial susceptibility to monoclonal antibody therapy. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.174799","journal-title":"JCI Insight"},{"issue":"7","key":"4593_CR101","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1128\/aac.04986-14","volume":"59","author":"Y Smani","year":"2015","unstructured":"Smani Y, Dom\u00ednguez-Herrera J, Ib\u00e1\u00f1ez-Mart\u00ednez J, Pach\u00f3n J (2015) Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii. Antimicrob Agents Chemother 59(7):3920\u20133924. https:\/\/doi.org\/10.1128\/aac.04986-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"4593_CR102","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.chembiol.2012.07.007","volume":"19","author":"MA Smith","year":"2012","unstructured":"Smith MA, Coin\u00e7on M, Paschos A, Jolicoeur B, Lavall\u00e9e P, Sygusch J, Baron C (2012) Identification of the binding site of Brucella VirB8 interaction inhibitors. Chem Biol 19(8):1041\u20131048. https:\/\/doi.org\/10.1016\/j.chembiol.2012.07.007","journal-title":"Chem Biol"},{"issue":"8","key":"4593_CR103","doi-asserted-by":"publisher","first-page":"16570","DOI":"10.3390\/ijms140816570","volume":"14","author":"SB Tay","year":"2013","unstructured":"Tay SB, Yew WS (2013) Development of quorum-based anti-virulence therapeutics targeting Gram-negative bacterial pathogens. Int J Mol Sci 14(8):16570\u201316599. https:\/\/doi.org\/10.3390\/ijms140816570","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4593_CR104","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1128\/aac.02606-12","volume":"57","author":"L Travier","year":"2013","unstructured":"Travier L, Rendueles O, Ferri\u00e8res L, Herry J-M, Ghigo J-M (2013) Escherichia coli resistance to nonbiocidal antibiofilm polysaccharides is rare and mediated by multiple mutations leading to surface physicochemical modifications. Antimicrob Agents Chemother 57(8):3960\u20133968. https:\/\/doi.org\/10.1128\/aac.02606-12","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4593_CR105","doi-asserted-by":"publisher","first-page":"e0306122","DOI":"10.1128\/spectrum.03061-22","volume":"11","author":"A Valcek","year":"2023","unstructured":"Valcek A, Philippe C, Whiteway C, Robino E, Nesporova K, Bov\u00e9 M, Coenye T, De Pooter T, De Coster W, Strazisar M, Van der Henst C (2023) Phenotypic characterization and heterogeneity among modern clinical isolates of Acinetobacter baumannii. Microbiol Spectr 11(1):e0306122. https:\/\/doi.org\/10.1128\/spectrum.03061-22","journal-title":"Microbiol Spectr"},{"key":"4593_CR106","doi-asserted-by":"publisher","unstructured":"van Fassen H, KuoLee R, Harris G, Zhao X, Conlan JW, Chen W (2007) Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun 75(12):5597\u20135608. https:\/\/doi.org\/10.1128\/iai.00762-07","DOI":"10.1128\/iai.00762-07"},{"key":"4593_CR107","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/621316","volume":"2014","author":"G Verbeken","year":"2014","unstructured":"Verbeken G, Huys I, Pirnay JP, Jennes S, Chanishvili N, Scheres J, G\u00f3rski A, De Vos D, Ceulemans C (2014) Taking bacteriophage therapy seriously: a moral argument. Biomed Res Int 2014:621316. https:\/\/doi.org\/10.1155\/2014\/621316","journal-title":"Biomed Res Int"},{"issue":"1","key":"4593_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14972-y","volume":"7","author":"X Vila-Farr\u00e9s","year":"2017","unstructured":"Vila-Farr\u00e9s X, Parra-Mill\u00e1n R, S\u00e1nchez-Encinales V, Varese M, Ayerbe-Algaba R, Bay\u00f3 N, Guardiola S, Pach\u00f3n-Ib\u00e1\u00f1ez ME, Kotev M, Garc\u00eda J, Teixid\u00f3 M, Vila J, Pach\u00f3n J, Giralt E, Smani Y (2017) Combating virulence of Gram-negative bacilli by OmpA inhibition. Sci Rep 7(1):14683. https:\/\/doi.org\/10.1038\/s41598-017-14972-y","journal-title":"Sci Rep"},{"issue":"7","key":"4593_CR109","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1128\/jb.185.7.2080-2095.2003","volume":"185","author":"VE Wagner","year":"2003","unstructured":"Wagner VE, Bushnell D, Passador L, Brooks AI, Iglewski BH (2003) Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: effects of growth phase and environment. J Bacteriol 185(7):2080\u20132095. https:\/\/doi.org\/10.1128\/jb.185.7.2080-2095.2003","journal-title":"J Bacteriol"},{"key":"4593_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01407","volume":"11","author":"C Wang","year":"2020","unstructured":"Wang C, Li P, Zhu Y, Huang Y, Gao M, Yuan X, Niu W, Liu H, Fan H, Qin Y, Tong Y, Mi Z, Bai C (2020) Identification of a novel Acinetobacter baumannii phage-derived depolymerase and its therapeutic application in mice. Front Microbiol 11:1407. https:\/\/doi.org\/10.3389\/fmicb.2020.01407","journal-title":"Front Microbiol"},{"issue":"11","key":"4593_CR111","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1017\/ice.2016.174","volume":"37","author":"LM Weiner","year":"2016","unstructured":"Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM (2016) Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011\u20132014. Infect Control Hosp Epidemiol 37(11):1288\u20131301. https:\/\/doi.org\/10.1017\/ice.2016.174","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"4593_CR112","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1128\/cmr.00058-16","volume":"30","author":"D Wong","year":"2017","unstructured":"Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B (2017) Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev 30(1):409\u2013447. https:\/\/doi.org\/10.1128\/cmr.00058-16","journal-title":"Clin Microbiol Rev"},{"key":"4593_CR113","unstructured":"World Health Organization (2020) 10 global health issues to track in 2021. https:\/\/www.who.int\/news-room\/spotlight\/10-global-health-issues-to-track-in-2021"},{"key":"4593_CR114","unstructured":"World Health Organization (2024) WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. World Health Organization. https:\/\/www.who.int\/publications\/i\/item\/9789240093461"},{"issue":"2","key":"4593_CR115","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nm989","volume":"10","author":"JJ Yan","year":"2004","unstructured":"Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, Jung KC, Cho JY, Nam JS, Suh HW, Kim YH, Song DK (2004) Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 10(2):161\u2013167. https:\/\/doi.org\/10.1038\/nm989","journal-title":"Nat Med"},{"key":"4593_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12121749","author":"Y Yao","year":"2023","unstructured":"Yao Y, Chen Q, Zhou H (2023) Virulence factors and pathogenicity mechanisms of Acinetobacter baumannii in respiratory infectious diseases. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics12121749","journal-title":"Antibiotics"},{"issue":"2","key":"4593_CR117","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1128\/aac.02183-13","volume":"58","author":"A Zaborin","year":"2014","unstructured":"Zaborin A, Defazio JR, Kade M, Kaiser BL, Belogortseva N, Camp DG 2nd, Smith RD, Adkins JN, Kim SM, Alverdy A, Goldfeld D, Firestone MA, Collier JH, Jabri B, Tirrell M, Zaborina O, Alverdy JC (2014) Phosphate-containing polyethylene glycol polymers prevent lethal sepsis by multidrug-resistant pathogens. Antimicrob Agents Chemother 58(2):966\u2013977. https:\/\/doi.org\/10.1128\/aac.02183-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"7995","key":"4593_CR118","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-023-06873-0","volume":"625","author":"C Zampaloni","year":"2024","unstructured":"Zampaloni C, Mattei P, Bleicher K, Winther L, Th\u00e4te C, Bucher C, Adam J-M, Alanine A, Amrein KE, Baidin V, Bieniossek C, Bissantz C, Boess F, Cantrill C, Clairfeuille T, Dey F, Di Giorgio P, du Castel P, Dylus D, Dzygiel P, Felici A, Garc\u00eda-Alcalde F, Haldimann A, Leipner M, Leyn S, Louvel S, Misson P, Osterman A, Pahil K, Rigo S, Sch\u00e4ublin A, Scharf S, Schmitz P, Stoll T, Trauner A, Zoffmann S, Kahne D, Young JAT, Lobritz MA, Bradley KA (2024) A novel antibiotic class targeting the lipopolysaccharide transporter. Nature 625(7995):566\u2013571. https:\/\/doi.org\/10.1038\/s41586-023-06873-0","journal-title":"Nature"},{"key":"4593_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1135180","volume":"14","author":"L Zeng","year":"2023","unstructured":"Zeng L, Lin F, Ling B (2023) Effect of traditional Chinese medicine monomers interfering with quorum-sensing on virulence factors of extensively drug-resistant Acinetobacter baumannii. Front Pharmacol 14:1135180. https:\/\/doi.org\/10.3389\/fphar.2023.1135180","journal-title":"Front Pharmacol"},{"key":"4593_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.961498","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Liu Y, Feng L, Xu M, Wen H, Yao Z, Shi S, Wu Q, Zhou C, Cao J, Zhou T (2022) In vitro and in vivo synergistic effect of chrysin in combination with colistin against Acinetobacter baumannii. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2022.961498","journal-title":"Front Microbiol"},{"key":"4593_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.558003","volume":"12","author":"S Zhong","year":"2021","unstructured":"Zhong S, He S (2021) Quorum sensing inhibition or quenching in Acinetobacter baumannii: the novel therapeutic strategies for new drug development. Front Microbiol 12:558003. https:\/\/doi.org\/10.3389\/fmicb.2021.558003","journal-title":"Front Microbiol"},{"key":"4593_CR122","doi-asserted-by":"publisher","unstructured":"Zhou J, Feng D, Li X, Chen Y, Zhang M, Wu W, Zhu J, Li H, Peng X, Zhang T (2024) L-Serine enables reducing the virulence of Acinetobacter baumannii and modulating the SIRT1 pathway to eliminate the pathogen. Microbiol Spectr 12(3):e0322623. https:\/\/doi.org\/10.1128\/spectrum.03226-23","DOI":"10.1128\/spectrum.03226-23"},{"key":"4593_CR123","doi-asserted-by":"publisher","DOI":"10.1093\/jambio\/lxac089","author":"JX Zhou","year":"2023","unstructured":"Zhou JX, Feng DY, Li X, Zhu JX, Wu WB, Zhang TT (2023) Advances in research on virulence factors of Acinetobacter baumannii and their potential as novel therapeutic targets. J Appl Microbiol. https:\/\/doi.org\/10.1093\/jambio\/lxac089","journal-title":"J Appl Microbiol"}],"container-title":["World Journal of Microbiology and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11274-025-04593-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11274-025-04593-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11274-025-04593-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:02:32Z","timestamp":1764021752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11274-025-04593-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":123,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4593"],"URL":"https:\/\/doi.org\/10.1007\/s11274-025-04593-3","relation":{},"ISSN":["0959-3993","1573-0972"],"issn-type":[{"value":"0959-3993","type":"print"},{"value":"1573-0972","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"424"}}